-
DETECTING SAFETY SIGNALS OF BILE ACID THERAPEUTICS: A FDA FAERS-BASED PHARMACOVIGILANCE STUDY
Feb 25, 2026, 14:40 PM -
PREVALENCE OF IMMUNOCOMPROMISED CONDITIONS AMONG PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW
Feb 25, 2026, 14:40 PM -
PREDICTORS OF GLP-1 RECEPTOR AGONIST USE AMONG U.S. ADULTS WITH COMORBID DEPRESSION AND TYPE 2 DIABETES MELLITUS
Feb 25, 2026, 14:40 PM -
REAL-WORLD DOSING AND DISCONTINUATION OF HYPERTENSION THERAPIES: INSIGHTS FROM A NATIONAL PHARMACY DATABASE
Feb 25, 2026, 14:40 PM -
MACHINE LEARNING-BASED PREDICTION OF 10-YEAR CORONARY HEART DISEASE RISK AND COMPARISON WITH THE FRAMINGHAM RISK SCORE
Feb 25, 2026, 14:40 PM -
REAL-WORLD TREATMENT PATTERNS AND TREATMENT INTENSIFICATION IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) BY DISEASE VOLUME AND PRESENTATION
Feb 25, 2026, 14:40 PM -
EVALUATING CLINICAL OUTCOME ASSESSMENTS IN LOW-RISK MYELODYSPLASTIC SYNDROMES THROUGH DEVELOPMENT OF A COMPREHENSIVE CONCEPTUAL MODEL BASED ON TARGETED LITERATURE REVIEWS AND CLINICIAN INTERVIEWS
Feb 25, 2026, 14:40 PM -
VALIDATION OF THE HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS CODE USING A LARGE-SCALE ELECTRONIC HEALTH RECORD DATABASE
Feb 25, 2026, 14:40 PM -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG WOMEN WITH VASOMOTOR SYMPTOMS (VMS) WITH AND WITHOUT DEPRESSION: A MEPS ANALYSIS
Feb 25, 2026, 14:40 PM -
THE FUTURE OF EVIDENCE SYNTHESIS AND GENERATION IN HEOR: A SECURE FRAMEWORK FOR DOMAIN SPECIFIC ADAPTATION AND FINE-TUNING OF LARGE LANGUAGE MODELS
Feb 25, 2026, 14:40 PM -
BUDGET IMPACT ANALYSIS OF DONISLECEL FOR ELIGIBLE ADULTS WITH TYPE I DIABETES IN THE UNITED STATES: AN ANALYSIS FROM A PAYER PERSPECTIVE
Feb 25, 2026, 14:40 PM -
OPTIMIZING RESOURCE ALLOCATION FOR SUSTAINABLE HIV TREATMENT: A TDABC ANALYSIS OF PROVIDER COSTS FOR ART IN ZIMBABWE
Feb 25, 2026, 14:40 PM -
PREVALENCE OF POLYCYSTIC OVARY SYNDROME (PCOS) AND BURDEN OF DISEASE AMONG WOMEN AGES 18-44 IN THE US, NATIONAL HEALTH AND WELLNESS SURVEY
Feb 25, 2026, 14:40 PM -
ACCESSIBILITY OF ANTI-TUBERCULOSIS DRUGS ON THE PHARMACEUTICAL MARKET IN THE ASIA-PACIFIC REGION BETWEEN 2019 AND 2022
Feb 25, 2026, 14:40 PM -
UNANCHORED MAIC VS STC FOR BINARY OUTCOMES: HOW BASELINE IMBALANCE IMPACTS ORR ESTIMATES
Feb 25, 2026, 14:40 PM -
COST-EFFECTIVENESS OF ABIRATERONE, APALUTAMIDE, ENZALUTAMIDE, AND DOCETAXEL DOUBLETS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A REAL-WORLD EVIDENCE ANALYSIS
Feb 25, 2026, 14:40 PM -
SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?
Feb 25, 2026, 14:40 PM -
IMPACT OF THE COVID-19 PANDEMIC ON HEALTHCARE EXPENDITURE AND RESOURCE USE IN PEOPLE LIVING WITH HIV IN THE UNITED STATES: A DIFFERENCE-IN-DIFFERENCE ANALYSIS
Feb 25, 2026, 14:40 PM -
OPTIMIZING THE INTEGRATION OF AI IN A COMPLEX SYSTEMATIC LITERATURE REVIEW: VALIDATION ACROSS TITLE/ABSTRACT AND FULL-TEXT STAGES
Feb 25, 2026, 14:40 PM -
COMPARISON OF 5-YEAR SURVIVAL AND ESTIMATED LIFE YEARS BETWEEN TWO DATA CUTS OF STUDY 309/KEYNOTE-775
Feb 25, 2026, 14:40 PM
